Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-08634404 and Chemotherapy in Extensive-Stage Small Cell Lung Cancer
NCT07226999Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Dec 2025
- Primary completion
- Jun 2030
- Modality
- Bispecific Antibodies
- Countries
- 10
01
Overview
Phase 3, randomised trial of PF-08634404 in small cell lung cancer (SCLC) (3 arms), sponsored by Pfizer. Primary endpoints: Objective Response Rate, Treatment-Emergent Adverse Events and 1 more. Started Dec 2025; status: recruiting.
02
Drugs
PF-08634404
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07226999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07226999.